Xencor, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XNCR | BINV.ST | OABI | ZYME | IDYA | CRVS | |
|---|---|---|---|---|---|---|
| Market cap | 2.60B | 252.69M | 755.56M | 2.22B | 3.13B | 889.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -9.9 | -1.0 | -19.9 | 25.5 | -7.9 | -9.9 |
| Price/book | 4.0 | 1.3 | 3.0 | 27.5 | 2.9 | 3.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +150.21% | −88.73% | +275.36% | +72.85% | +8.41% | +35.17% |
| Today | +14.33% | +7.11% | +0.58% | +2.69% | +3.29% | +7.53% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XNCR news ›Xencor Shares Jump 20% to 52-Week High as Kidney Cancer Drug XmAb819 Shows 45.5% Response Rate in Early Trial
Shares of Xencor Inc. jumped nearly 20% on Monday to their highest level in a year. The biotechnology company presented early clinical data showing its experimental kidney cancer drug shrank tumors in nearly half of the patients treated at…
Xencor Stock Rises 20.25% on Updated Trial Data for XmAb819 in ccRCC
Xencor shares traded 20.25% higher at $30.27 at publication on Monday. Benzinga Pro data showed the shares approaching the 52-week high of $30.61. Xencor presented updated Phase 1 findings for XmAb819 in advanced clear cell renal cell…
Xencor (XNCR) Expected to Post Quarterly Earnings on Wednesday
Posted by Tristan Rich on Oct 28th, 2026 Shares of Xencor stock opened at $29.99 on Wednesday. Xencor has a 12-month low of $10.38 and a 12-month high of $33.60. The firm’s 50 day simple moving average is $25.56 and its two-hundred day…
BlackRock Reveals 14.5% Ownership Stake in Xencor Through 13G Amendment Filing
Why Did Northern Star Reject the Gold Fields (NYSE:GFI) Approach? What Did Kinross Gold (NYSE:KGC) Change Before Its Q3 Results Day? On October 27, 2026, BlackRock, Inc. submitted Amendment No. 7 to its Schedule 13G with the SEC, reporting…
Xencor soars 16% on encouraging early XmAb819 data
Shares of Xencor ( XNCR ), a clinical-stage biopharmaceutical company focused on engineered antibody therapeutics for cancer and autoimmune diseases, jumped almost 16% on Monday. This followed the ... SA Spotlight uses AI to summarize…
Xencor (NASDAQ:XNCR) Stock Price Target Raised at Wedbush
Posted by Defense World Staff on Oct 28th, 2026 Xencor (NASDAQ:XNCR – Free Report) had its price target raised by Wedbush from $30.00 to $45.00 in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm currently…
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. Click to read. - Xencor maintains a "Strong Buy" rating following positive phase 1…
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- Details of the Proffered Paper Oral…
Xencor Catapults, Breaking Out On 'Unprecedented,' 'Profound' Cancer Data
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma - Slideshow
2026-10-27. The following slide deck was published by Xencor, Inc. The following slide deck was published by Xencor, Inc. in conjunction with this event.
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- seekingalpha.com3
- themarketsdaily.com3
- defenseworld.net1
- ibtimes.com.au1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.